Parkinson disease: an update.
暂无分享,去创建一个
[1] Paul Crawford,et al. Differentiation and diagnosis of tremor. , 2011, American family physician.
[2] J. Patterson,et al. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland , 2009, Movement disorders : official journal of the Movement Disorder Society.
[3] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[4] K. Sethi,et al. A controlled trial of antidepressants in patients with Parkinson’s disease and depression , 2009, Current neurology and neuroscience reports.
[5] C. Warren Olanow,et al. The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.
[6] D. Aarsland,et al. Excessive daytime sleepiness in Parkinson disease , 2006, Neurology.
[7] A. Hout,et al. Dementia and survival in Parkinson disease , 2008, Neurology.
[8] W. Weiner,et al. Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) , 2006, Neurology.
[9] H. Braak,et al. A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.
[10] C. Ramaker,et al. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. , 2007, The Cochrane database of systematic reviews.
[11] W. Weiner,et al. Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease , 2010, Neurology.
[12] F. Horak,et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.
[13] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[14] H. Guchelaar,et al. Glycopyrrolate for sialorrhea in Parkinson disease , 2010, Neurology.
[15] C. Clarke,et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. , 2010, The Cochrane database of systematic reviews.
[16] P. A. House,et al. Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .
[17] M. Mahowald,et al. Rapid eye movement sleep parasomnias. , 2005, Neurologic clinics.
[18] B. Mollenhauer,et al. Associated factors for REM sleep behavior disorder in Parkinson disease , 2011, Neurology.
[19] C. Counsell,et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. , 2009, The Cochrane database of systematic reviews.
[20] Goutham Rao,et al. Does this patient have Parkinson disease? , 2003, JAMA.
[21] M. Hely,et al. Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.
[22] W. Weiner,et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[23] J. Ferreira,et al. Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.
[24] G. Deuschl,et al. A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.
[25] Shalini Jha,et al. The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
[26] Albert Hofman,et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. , 2005, Archives of neurology.
[27] S. Reich,et al. The use of alternative therapies by patients with Parkinson’s disease , 2001, Neurology.
[28] E. Montgomery. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2007, Neurology.
[29] W. Poewe,et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[30] Y Ben-Shlomo,et al. How valid is the clinical diagnosis of Parkinson's disease in the community? , 2002, Journal of neurology, neurosurgery, and psychiatry.
[31] G. Logroscino,et al. Parkinson disease and risk of mortality , 2008, Neurology.
[32] A. E. Lang,et al. Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review , 2002, Neurology.
[33] S. Spieker,et al. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. , 2004, The Cochrane database of systematic reviews.
[34] M. Hallett,et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[35] J. Friedman,et al. Fatigue in levodopa-naïve subjects with Parkinson disease , 2008, Neurology.